Windlas Biotech AAQS
The The AAQS of Windlas Biotech (WINDLAS.NS) as of Nov 3, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
4
YoY
0.00%
Last updated:
Windlas Biotech has a current AAQS of 4.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Windlas Biotech in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Windlas Biotech in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The Windlas Biotech AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2019
4.00 INR
Jan 1, 2020
4.00 INR
Jan 1, 2021
4.00 INR
Jan 1, 2022
4.00 INR
Jan 1, 2023
4.00 INR
Jan 1, 2024
4.00 INR
Jan 1, 2025
4.00 INR
Jan 1, 2026
4.00 INR
| YEAR | AAQS | YoY |
|---|---|---|
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Windlas Biotech Stock analysis
What does Windlas Biotech do? Windlas Biotech Ltd. generates revenue through its CDMO services, offering product discovery, development, licensing, and commercial manufacturing for generic and complex generic pharmaceuticals across therapeutic areas like anti-diabetic, cardiovascular, neuropsychiatry, and respiratory therapies. The company provides formulation development, technology scale-up, and full-scale manufacturing for solid and liquid dosage forms, serving clients in the pharmaceutical industry. Additionally, Windlas markets its own nutraceutical, pharmaceutical, and ayurvedic products through a salesforce and distribution network spanning over 14 states, targeting semi-urban and rural communities. Its manufacturing facilities in Dehradun support both CDMO operations and in-house product production.
The company's primary clients for CDMO services are pharmaceutical firms seeking development and manufacturing solutions for generic drugs. These clients benefit from Windlas's capabilities in formulation development, scale-up, and commercial production. The firm's own product line, sold via its distribution network, reaches semi-urban and rural consumers in India, complementing its CDMO business. Manufacturing in Dehradun enables efficient production for both external clients and internal product lines.
Windlas Biotech's revenue streams include contract manufacturing for pharmaceutical companies and direct sales of its branded nutraceutical, pharmaceutical, and ayurvedic products. The CDMO segment focuses on complex generics in key therapeutic categories, while the in-house product line targets underserved communities with accessible healthcare solutions. The dual approach leverages the company's manufacturing infrastructure to serve both business-to-business and business-to-consumer markets. Windlas Biotech is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Windlas Biotech stock
The AAQS of Windlas Biotech is 4 in 2026.
On Eulerpool you can find the complete historical development of The AAQS Windlas Biotech since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Windlas Biotech
All Key Metrics — Windlas Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth